Literature DB >> 32187361

Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.

Stuart E Lacy1, Sharon L Barrans2, Philip A Beer3, Daniel Painter1, Alexandra G Smith1, Eve Roman1, Susanna L Cooke4, Camilo Ruiz3, Paul Glover2, Suzan J L Van Hoppe2, Nichola Webster2, Peter J Campbell3, Reuben M Tooze5, Russell Patmore6, Cathy Burton2, Simon Crouch1, Daniel J Hodson7.   

Abstract

Based on the profile of genetic alterations occurring in tumor samples from selected diffuse large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies proposed partially overlapping classification systems. Using clustering techniques applied to targeted sequencing data derived from a large unselected population-based patient cohort with full clinical follow-up (n = 928), we investigated whether molecular subtypes can be robustly identified using methods potentially applicable in routine clinical practice. DNA extracted from DLBCL tumors diagnosed in patients residing in a catchment population of ∼4 million (14 centers) were sequenced with a targeted 293-gene hematological-malignancy panel. Bernoulli mixture-model clustering was applied and the resulting subtypes analyzed in relation to their clinical characteristics and outcomes. Five molecular subtypes were resolved, termed MYD88, BCL2, SOCS1/SGK1, TET2/SGK1, and NOTCH2, along with an unclassified group. The subtypes characterized by genetic alterations of BCL2, NOTCH2, and MYD88 recapitulated recent studies showing good, intermediate, and poor prognosis, respectively. The SOCS1/SGK1 subtype showed biological overlap with primary mediastinal B-cell lymphoma and conferred excellent prognosis. Although not identified as a distinct cluster, NOTCH1 mutation was associated with poor prognosis. The impact of TP53 mutation varied with genomic subtypes, conferring no effect in the NOTCH2 subtype and poor prognosis in the MYD88 subtype. Our findings confirm the existence of molecular subtypes of DLBCL, providing evidence that genomic tests have prognostic significance in non-selected DLBCL patients. The identification of both good and poor risk subtypes in patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) clearly show the clinical value of the approach, confirming the need for a consensus classification.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32187361      PMCID: PMC7259825          DOI: 10.1182/blood.2019003535

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  25 in total

1.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.

Authors:  Jens G Lohr; Petar Stojanov; Michael S Lawrence; Daniel Auclair; Bjoern Chapuy; Carrie Sougnez; Peter Cruz-Gordillo; Birgit Knoechel; Yan W Asmann; Susan L Slager; Anne J Novak; Ahmet Dogan; Stephen M Ansell; Brian K Link; Lihua Zou; Joshua Gould; Gordon Saksena; Nicolas Stransky; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Enrique Hernández-Lemus; Angela Schwarz-Cruz y Celis; Ivan Imaz-Rosshandler; Akinyemi I Ojesina; Joonil Jung; Chandra S Pedamallu; Eric S Lander; Thomas M Habermann; James R Cerhan; Margaret A Shipp; Gad Getz; Todd R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-17       Impact factor: 11.205

2.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

3.  Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network.

Authors:  Daniel Painter; Sharon Barrans; Stuart Lacy; Alexandra Smith; Simon Crouch; David Westhead; Chulin Sha; Russell Patmore; Reuben Tooze; Cathy Burton; Eve Roman
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

4.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.

Authors:  Stefano Monti; Bjoern Chapuy; Kunihiko Takeyama; Scott J Rodig; Yansheng Hao; Kelly T Yeda; Haig Inguilizian; Craig Mermel; Treeve Currie; Ahmet Dogan; Jeffery L Kutok; Rameen Beroukhim; Donna Neuberg; Thomas M Habermann; Gad Getz; Andrew L Kung; Todd R Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2012-09-11       Impact factor: 31.743

5.  Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.

Authors:  Yucai Wang; Brian K Link; Thomas E Witzig; Matthew J Maurer; Cristine Allmer; Rebecca L King; Andrew L Feldman; Thomas M Habermann; Stephen M Ansell; Susan L Slager; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

6.  Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.

Authors:  Ji Yuan; George Wright; Andreas Rosenwald; Christian Steidl; Randy D Gascoyne; Joseph M Connors; Anja Mottok; Dennis D Weisenburger; Timothy C Greiner; Kai Fu; Lynette Smith; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; German Ott; Julie M Vose; Louis M Staudt; Wing C Chan
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

7.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

8.  PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.

Authors:  Vamsi K Mootha; Cecilia M Lindgren; Karl-Fredrik Eriksson; Aravind Subramanian; Smita Sihag; Joseph Lehar; Pere Puigserver; Emma Carlsson; Martin Ridderstråle; Esa Laurila; Nicholas Houstis; Mark J Daly; Nick Patterson; Jill P Mesirov; Todd R Golub; Pablo Tamayo; Bruce Spiegelman; Eric S Lander; Joel N Hirschhorn; David Altshuler; Leif C Groop
Journal:  Nat Genet       Date:  2003-07       Impact factor: 38.330

9.  Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Authors:  Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt
Journal:  N Engl J Med       Date:  2018-04-12       Impact factor: 91.245

10.  Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort.

Authors:  Alexandra Smith; Debra Howell; Simon Crouch; Dan Painter; John Blase; Han-I Wang; Ann Hewison; Timothy Bagguley; Simon Appleton; Sally Kinsey; Cathy Burton; Russell Patmore; Eve Roman
Journal:  Int J Epidemiol       Date:  2018-06-01       Impact factor: 7.196

View more
  74 in total

Review 1.  Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Authors:  Siba El Hussein; Kenna R M Shaw; Francisco Vega
Journal:  Mod Pathol       Date:  2020-07-03       Impact factor: 7.842

Review 2.  Treatment resistance in diffuse large B-cell lymphoma.

Authors:  Michael Y He; Robert Kridel
Journal:  Leukemia       Date:  2021-05-20       Impact factor: 11.528

3.  Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.

Authors:  Christopher K Rushton; Sarah E Arthur; Miguel Alcaide; Matthew Cheung; Aixiang Jiang; Krysta M Coyle; Kirstie L S Cleary; Nicole Thomas; Laura K Hilton; Neil Michaud; Scott Daigle; Jordan Davidson; Kevin Bushell; Stephen Yu; Ryan N Rys; Michael Jain; Lois Shepherd; Marco A Marra; John Kuruvilla; Michael Crump; Koren Mann; Sarit Assouline; Joseph M Connors; Christian Steidl; Mark S Cragg; David W Scott; Nathalie A Johnson; Ryan D Morin
Journal:  Blood Adv       Date:  2020-07-14

4.  Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.

Authors:  Wyndham H Wilson; George W Wright; Da Wei Huang; Brendan Hodkinson; Sriram Balasubramanian; Yue Fan; Jessica Vermeulen; Martin Shreeve; Louis M Staudt
Journal:  Cancer Cell       Date:  2021-11-04       Impact factor: 31.743

5.  Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.

Authors:  Takashi Ishio; Sarvesh Kumar; Joji Shimono; Anusara Daenthanasanmak; Sigrid Dubois; Yuquan Lin; Bonita Bryant; Michael N Petrus; Emmanuel Bachy; Da Wei Huang; Yandan Yang; Patrick L Green; Hiroo Hasegawa; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takashi Yokota; Kanako C Hatanaka; Yutaka Hatanaka; Shinya Tanaka; Yoshihiro Matsuno; Yibin Yang; Satoshi Hashino; Takanori Teshima; Thomas A Waldmann; Louis M Staudt; Masao Nakagawa
Journal:  Blood       Date:  2022-03-10       Impact factor: 22.113

6.  Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.

Authors:  Leo Meriranta; Annika Pasanen; Amjad Alkodsi; Jari Haukka; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Blood Adv       Date:  2020-08-11

7.  Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.

Authors:  Adam R Davis; Sara L Stone; Amanda R Oran; Robyn T Sussman; Siddharth Bhattacharyya; Jennifer J D Morrissette; Adam Bagg
Journal:  Mod Pathol       Date:  2020-12-12       Impact factor: 7.842

8.  Epstein-Barr virus positive diffuse large B-cell lymphoma transformed into angioimmunoblastic T-cell lymphoma after treatment.

Authors:  Chaoyu Wang; Yi Gong; Qingming Jiang; Xiping Liang; Rui Chen
Journal:  Clin Case Rep       Date:  2021-05-05

Review 9.  Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications.

Authors:  Sotirios G Papageorgiou; Thomas P Thomopoulos; Ioannis Katagas; Anthi Bouchla; Vassiliki Pappa
Journal:  Ther Adv Hematol       Date:  2021-05-24

Review 10.  Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.

Authors:  Etienne Leveille; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.